## UNIVERSITY<sup>OF</sup> BIRMINGHAM University of Birmingham Research at Birmingham

# Alterations in protein kinase A substrate specificity as a potential cause of Cushing's Syndrome

Bathon, Kerstin; Wigand, Isabel; Vanselow, Jens T.; Ronchi, Cristina; Sbiera, Silviu; Schlosser, Andreas; Calebiro, Davide; Fassnacht, Martin

DOI: 10.1210/en.2018-00775

License: Other (please specify with Rights Statement)

Document Version Peer reviewed version

#### Citation for published version (Harvard):

Bathon, K, Wigand, I, Vanselow, JT, Ronchi, C, Sbiera, S, Schlosser, A, Calebiro, D & Fassnacht, M 2019, 'Alterations in protein kinase A substrate specificity as a potential cause of Cushing's Syndrome', *Endocrinology*, vol. 160, no. 2, pp. 447-459. https://doi.org/10.1210/en.2018-00775

Link to publication on Research at Birmingham portal

#### **Publisher Rights Statement:**

This is a pre-copyedited, author-produced PDF of an article accepted for publication in Endocrinology following peer review. The version of record Kerstin Bathon, Isabel Weigand, Jens T Vanselow, Cristina L Ronchi, Silviu Sbiera, Andreas Schlosser, Martin Fassnacht, Davide Calebiro; Alterations in Protein Kinase A Substrate Specificity as a Potential Cause of Cushing Syndrome, Endocrinology, Volume 160, Issue 2, 1 February 2019, Pages 447–459, https://doi.org/10.1210/en.2018-00775 is available online at: https://doi.org/10.1210/en.2018-00775

#### **General rights**

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

•Users may freely distribute the URL that is used to identify this publication.

•Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.

•User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?) •Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

#### Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

## Alterations in Protein Kinase A Substrate Specificity as a Potential Cause of Cushing's Syndrome

Kerstin Bathon<sup>1</sup>, Isabel Weigand<sup>2</sup>, Jens T. Vanselow<sup>3</sup>, Cristina L. Ronchi<sup>2,5,6</sup>, Silviu Sbiera<sup>2</sup>, Andreas Schlosser<sup>3</sup>, Martin Fassnacht<sup>2,4</sup>, Davide Calebiro<sup>1,5,7\*</sup>

<sup>1</sup> Institute of Pharmacology and Toxicology and Bio-Imaging Center, University of Würzburg, 97078 Würzburg, Germany

<sup>2</sup> Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of Würzburg, 97080 Würzburg, Germany

- <sup>3</sup> Rudolf Virchow Center, University of Würzburg, 97080 Würzburg, Germany
- <sup>4</sup> Central Laboratory, University Hospital Würzburg, 97080 Würzburg, Germany
- <sup>5</sup> Institute of Metabolism and Systems Research (IMSR), University of Birmingham, B15 2TT Birmingham, UK

<sup>6</sup> Centre for Endocrinology, Diabetes and Metabolism (CEDAM), Birmingham Health Partners, B15 2TT Birmingham, UK

<sup>7</sup> Centre of Membrane Proteins and Receptors (COMPARE), B15 2TT Birmingham, UK

Short title: Mutations in adrenal Cushing alter PKA specificity

Keywords: PKA, Cushing's syndrome, PRKACA mutations

\* Address correspondence and material requests to: Davide Calebiro MD PhD DSc
Institute of Metabolism and Systems Research
College of Medical and Dental Sciences
Edgbaston
Birmingham
B15 2TT
Tel. +44 (0) 121 414 3928
Fax. +44 (0) 121 415 8712

#### Funding

This study was supported by the IZKF Würzburg (grant B-281 to D.C. and M.F.), the ERA-NET "E-Rare" (grant 01GM1407B to M.F. and D.C.) and the Deutsche Forschungsgemeinschaft (SFB/Transregio 166–Project C1 to D.C. and SFB/Transregio 205/1 to M.F.). KB was partially supported by a grant of the German Excellence Initiative to the Graduate School of Life Sciences, University of Würzburg. The tumor samples were stored at the Interdisciplinary Bank of Biomaterials and Data of the University Hospital of Würzburg and the Julius Maximilian University of Würzburg (idbw). The implementation of idbw has been supported by a grant of the Federal Ministry for Education and Research (Grant number FKZ: 01EY1102).

Disclosure Summary: The authors have nothing to disclose.

#### 1 Abstract

2 Cushing's syndrome is a severe endocrine disorder of cortisol excess, associated with major 3 metabolic and cardiovascular sequelae. We recently identified somatic mutations in the gene 4 (*PRKACA*) encoding the catalytic  $\alpha$  (C $\alpha$ ) subunit of protein kinase A (PKA) to be responsible 5 for cortisol-producing adrenocortical adenomas (CPAs), which are a major cause of 6 Cushing's syndrome. In spite of previous studies on the two initially identified mutations 7 (L206R, 199\_200insW), the mechanisms of action of the clinically highly relevant PRKACA 8 mutations remain poorly understood. Here, by investigating a large panel of PRKACA 9 mutations including all those identified so far in Cushing's syndrome, we unexpectedly find 10 that not all mutations interfere with the binding of regulatory (R) subunits as previously 11 hypothesized. Since several mutations lie in a region of PKA  $C\alpha$  involved in substrate 12 recognition, we have investigated their consequences on substrate specificity by quantitative 13 phosphoproteomics. We find that all three mutations analyzed (L206R, 200 201insV and 14 d244-248+E249Q) cause major changes in the preference of PKA for its targets, leading to hyperphosphorylation of several PKA substrates, including most notably histone H1.4 at 15 16 Ser36, which is required for and promotes mitosis. This is reflected by a 9-fold hyperphosphorylation of H1.4 in CPAs carrying the L206R mutation. Thus, our findings 17 suggest that besides hampering binding to R subunits, PRKACA mutations act via altering 18 19 PKA substrate specificity. These findings shed new light on the molecular events leading to 20 Cushing's syndrome and provide an illustrative example of how mutations altering substrate 21 specificity of a protein kinase might cause human disease.

#### 22 Introduction

Cushing's syndrome is an endocrine disease characterized by cortisol excess. If not promptly recognized and treated, it is associated with severe morbidity and increased mortality, mostly due to metabolic and cardiovascular sequelae, such as diabetes mellitus, osteoporosis and hypertension (1,2). Beside ACTH-producing pituitary adenomas, cortisolproducing adenomas of the adrenal are the major cause of endogenous Cushing's syndrome (3).

Protein kinase A (PKA) is the main intracellular mediator of the ubiquitous second 29 messenger cyclic AMP (cAMP), which is produced in response to several hormones and 30 31 neurotransmitters (4,5). In its inactive state, PKA is a tetrameric complex composed of two 32 regulatory (R) and two catalytic (C) subunits (5), which exist in different isoforms - three for 33 C ( $\alpha$ ,  $\beta$ ,  $\gamma$ ) and four for R (I $\alpha$ , I $\beta$ , II $\alpha$ , II $\beta$ ) subunits, each encoded by a separate gene (6). 34 Additionally, protein kinase X (PrKX) can also form holoenzymes with R subunits (7). In the 35 inactive complex, two short linear segments emanating from each R subunit, known as 36 inhibitory sequences, act as substrates (RII) or pseudo-substrates (RI) that occupy the active 37 site clefts of the C subunits, thus preventing the access of other substrates (5,8,9); this keeps PKA in the inactive state (5,8,9). Binding of cAMP to two distinct sites on each R 38 39 subunit induces their dissociation from the C subunits, allowing the C subunits to 40 phosphorylate a large number of PKA substrates located in both the cytosol and the nucleus 41 (5,8,9).

Our group has recently discovered that somatic mutations in the gene coding for the C $\alpha$ subunit of PKA (*PRKACA*) are responsible for Cushing's syndrome due to cortisol-producing adrenocortical adenomas (CPAs) (10-13). These findings have been independently confirmed by other groups (14-18). Very recently, rare mutations in the gene coding for the C $\beta$  subunit of PKA (*PRKACB*) have also been found in CPAs (19). Between 23 and 67% of all CPAs carry a recurrent mutation (L206R) of a residue in the C $\alpha$  subunit that is involved in the interaction with the R subunits (10,11,14-16). By screening a large group of CPAs, we

49 have in the meantime identified six additional *PRKACA* mutations (199\_200insW, 50 S213R+insIILR, 200\_201insV, W197R, d244-248+E249Q and E32V) in unilateral adenomas 51 of patients affected by overt Cushing's syndrome (10-12). With one exception (E32V), all 52 identified mutations lie in a hot spot region on the surface of the C $\alpha$  subunit that is adjacent 53 to the active site cleft and faces the R subunit (12).

54 Whereas all previous studies provide strong evidence for a causal role of PRKACA 55 mutations, the mechanisms linking these mutations to increased cell proliferation and cortisol 56 secretion in adrenocortical cells are still debated (10,14-16). One of the initial studies 57 suggested that the L206R mutation increases PKA activity by enhancing substrate 58 interaction and/or the catalytic activity of the enzyme (14). In contrast, two other studies suggested that the L206R mutation might prevent binding of the R subunit (15,16). In strong 59 support of this possibility, we subsequently demonstrated that the two initially identified 60 61 mutations (L206R and 199\_200insW) interfere with the formation of a stable complex with R 62 subunits, thus rendering mutated  $C\alpha$  subunits constitutively active (13). However, we did not 63 observe increased catalytic activity (13). Whereas these data indicate that a reduced 64 interaction with R subunits is likely involved in the pathogenesis of Cushing's syndrome - at least in the case of the two investigated PRKACA mutations (L206R and 199\_200insW) -65 66 additional mechanisms might play an equally important role.

Here, we report a comprehensive functional characterization of all *PRKACA* mutations identified so far. Unexpectedly, our results indicate that besides interfering with the binding of R subunits, *PRKACA* mutations cause major changes in the preference of PKA for its targets, leading to hyperphosphorylation of several PKA substrates, including most notably histone H1.4 at Ser36, which is required for and promotes mitosis (20).

#### 72 Methods

#### 73 Plasmids

74 Plasmids encoding human RIa, RIIB and RIIB-FLAG were described earlier (13). A plasmid encoding human wild-type  $C\alpha$  was purchased from Origene. Mutations in the coding 75 sequence of  $C\alpha$  were introduced by PCR as previously described (10). To generate a 76 plasmid encoding a FLAG-tagged RI $\alpha$  subunit, a fragment containing the entire coding 77 sequence of the human RI $\alpha$  subunit was amplified by PCR with a forward primer containing 78 79 the FLAG tag (amino-acid sequence DYKDDDDA) and a HindIII site at the 5' and a reverse 80 primer containing a Notl site at the 3'. This fragment was subsequently cloned between the 81 HindIII and Notl sites of pcDNA3.

82

#### 83 Tumor tissue

84 A total of 8 snap-frozen tumor specimens from CPAs were investigated. All samples were collected at the University Hospital of Würzburg. Six of these samples had been included in 85 previous reports from our group: three in Ronchi et al. (12) and three in Beuschlein et al. 86 (10). According to our previous sequencing data, four CPA samples harbored somatic 87 88 PRKACA mutations. In particular, three samples from patients with overt Cushing's 89 syndrome presented a L206R substitution and one sample from a patient with mild 90 autonomous cortisol secretion (subclinical Cushing's syndrome) presented a d244-91 248+E249Q mutation. The four remaining CPAs were PRKACA wild-type. The collection of 92 the clinical data and the biomaterial for this retrospective study was approved by the ethics 93 committee of the University of Würzburg (approvals no. 93/02 and 88/11). Written informed 94 consent was obtained from all patients.

95

#### 96 Cell culture and transfection

97 HEK293A cells were obtained from ATCC. Cells were cultured in Dulbecco's modified
98 Eagle's medium (DMEM) supplemented with 10% FCS, 0.1 mg/ml streptomycin and 100

99 U/ml penicillin at 37 °C, 5% (vol/vol) CO2. HEK293A cells were seeded at a density of 3.5x10<sup>6</sup> cells/15-cm Petri dish, 1.2 x 10<sup>6</sup> cells/10-cm Petri dish or 0.25 x 10<sup>6</sup> cells/well onto 6-100 101 well plates and allowed to grow for 24 h, after which they were transfected with the Effectene 102 transfection kit (Qiagen) according to the manufacturer's protocol. A 1:8 ratio of transfected 103 C and R subunit DNAs was used to favor association between C and R subunits (10). All 104 experiments were performed 48 h after transfection. For SILAC labeling, the cells were 105 grown in light (Lys0, Arg0) or heavy (Lys8, Arg10) labeled DMEM supplemented with 10% 106 dialyzed FCS and 0.1 mg/ml streptomycin and 100 U/ml penicillin for at least 6 passages 107 before the experiment.

108

#### 109 **Preparation of cell lysates**

110 Cells were washed with ice-cold phosphate-buffered saline (PBS), scraped off plates, and 111 resuspended in 300  $\mu$ l 5/2 buffer (5 mM Tris-HCl, 2 mM EDTA, pH 7.4). Thereafter, samples 112 were homogenized using an Ultraturrax device for 20 s on ice and centrifuged at 50,000 x *g* 113 for 30 min at 4 °C to remove membranes.

114

#### 115 **Preparation of total cell lysates**

116 Cells were washed once with PBS. Then, 2 ml of lysis buffer (8M urea, 1 mM sodium 117 vanadate, 2.5 mM pyrophosphate, 1 mM  $\beta$ -glycerophosphate, 20mM HEPES, pH 8.0) 118 supplemented with the cOmplete Mini EDTA-free protease inhibitor cocktail (Roche) were 119 added to each 15-cm Petri dish and the cells were scraped into the buffer. Cell suspensions 120 were sonicated three times for 15 sec each and lysates were cleared by centrifugation at 121 4,000 rpm for 1 h at 15 °C.

122

#### 123 PKA activity assay

PKA catalytic activity was measured on cell lysates using the PepTag non-radioactivecAMP-dependent protein kinase assay (Promega), which uses fluorescent kemptide as a

substrate, following the manufacturer's instructions. Images of the gels were acquired with a gel documentation system (Herolab) and analyzed using the ImageJ software (http://rsbweb.nih.gov/ij). Endogenous PKA activity was subtracted and values were normalized to the value of the stimulated wild-type.

130

#### 131 **Co-immunoprecipitation**

132 Cells were lysed with a buffer containing 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 20 mM Tris-HCI, pH 7.5, supplemented with cOmplete Mini protease inhibitor 133 cocktail (Roche). Lysates were centrifuged at 20,000 x g for 10 min at 4 °C. Supernatants 134 were transferred to a new vial and incubated with protein-A sepharose for 2 h at 4 °C under 135 136 continuous rotation. Protein-A sepharose was preincubated with a mouse monoclonal anti-137 FLAG antibody (Sigma-Aldrich, # F3165). Preincubations were performed overnight at 4 °C 138 under continuous rotation. After the incubation of protein-A sepharose with the cell lysates, 139 samples were washed 5 times with lysis buffer. Proteins were recovered from protein-A 140 sepharose by addition of Laemmli buffer, followed by incubation at 95 °C for 3 min. After Western blot analysis and quantification, the amount of  $C\alpha$  was normalized to that in the 141 142 wild-type sample.

143

#### 144 **Histone extraction**

Histones were acid-extracted from cells and CPA samples as described by Shechter et al. (21). Briefly, harvested cells or Douncer-homogenized tissue samples were lysed in a hypotonic lysis buffer (150 mM Tris/HCl, 1 mM KCl, 1.5 mM MgCl<sub>2</sub>, 1 mM DTT, pH 8.0) supplemented with 0.5  $\mu$ g/ml leupeptin, 2  $\mu$ g/ml aprotinin, 0.1 mM phenylmethylsulfonyl fluoride (PMSF), the cOmplete Mini protease inhibitor cocktail (Roche) and a phosphatase inhibitor cocktail (Roche). Lysates were then acid-extracted with H<sub>2</sub>SO<sub>4</sub> for 30 min followed by precipitation with trichloroacetic acid and resuspension in H<sub>2</sub>O.

152

#### 153 Western blot analysis

154 Samples were mixed with Laemmli buffer and incubated at 95 °C for 3 min. Proteins were 155 separated by electrophoresis on either a 10% or 15% (for histone H1.4) SDS polyacrylamide gel and electro-transferred to a PVDF membrane (Merck Millipore). Membranes were 156 157 blocked with Tris-buffered saline supplemented with 1% Tween and 5% skim milk powder or bovine serum albumin (antibodies detecting phosphoproteins) for 1 hour at RT, and 158 159 incubated overnight at 4 °C with the indicated primary antibody, followed by incubation with 160 horseradish peroxidase-conjugated secondary antibodies for 1 h at RT. PKA Ca subunits were detected with a rabbit polyclonal antibody (Cell Signaling #4782, 1:7,000 dilution). 161 162 FLAG-tagged R subunits were detected using a rabbit monoclonal anti-FLAG antibody 163 (Sigma-Aldrich, #F7425, 1:4,000 dilution). PKA RIa subunits were detected using a mouse 164 monoclonal antibody (BD Transduction Lab., #610609, 1:1,000 dilution) and RIIB subunits with a mouse monoclonal antibody (BD Transduction Lab., #610625, 1:2,000 dilution). 165 166 Phosphorylated PKA substrates were detected using a rabbit polyclonal antibody (Cell 167 Signaling, #9621, 1:1,000 dilution). A rabbit polyclonal antibody (ThermoFisher, #PA5-168 31908, 1:2,000 dilution) and a rabbit polyclonal antibody (ThermoFisher, #PA5-31907, 169 1:1,000 dilution) was used for total histone H1.4 and Ser36 phosphorylated histone H1.4, 170 respectively.

171

#### 172 Substrate specificity of PKA Cα mutants *in silico*

The *in silico* prediction was done using the Kinase Substrate Prediction v 2.0 algorithm (22). This algorithm predicts substrate specificity based on the primary amino acid sequence of more than 488 human protein kinase catalytic domains and 10,000 known kinase–substrate phosphosite pairs. The algorithm computes a specificity matrix for a given kinase, or mutant thereof, where values indicate the relative preference for each amino acid at each position around the phosphoacceptor site. Only relevant changes are reported.

179

#### 180 Substrate specificity of PKA Cα mutants *in vitro*

181 Mutant and wild-type samples were labelled with heavy and light amino acids as described 182 in cell culture and transfection. Before preparing total cell lysates, the cells were stimulated with 10 µM forskolin for 30 min. Protein concentration of the total cell lysates were 183 184 determined using the BCA assay. Before processing the samples for phosphoproteomics, an 185 input sample for proteome analysis was taken, which was digested with trypsin and analysed 186 by nano LC-MS/MS. For phosphoproteomics experiments, no more than 20 mg protein were 187 used. Substrate specificity was assessed using the PTMScan Phospho-PKA Substrate Motif 188 (RRXS\*/T\*) Kit (Cell Signaling, #5565) following the manufacturer's instructions - see Supplementary Data (23) for details. The dried peptides were stored at -20°C until the nano 189 190 LC-MS/MS analysis.

191

#### 192 Nano LC-MS/MS analysis

Nanoscale liquid chromatography coupled to tandem mass spectrometry (nano LC-MS/MS) analyses were performed on an Orbitrap Fusion system (Thermo Scientific) equipped with an EASY-Spray Ion Source and coupled to an EASY-nLC 1000 (Thermo Scientific). Peptides, resuspended in 2% acetonitrile and 0.1% formic acid, were loaded on a trapping column (2 cm x 75 µm ID, PepMap C18, 3 µm particles, 100 Å pore size) and separated on an EASY-Spray column (50 cm x 75 µm ID, PepMap C18, 2 µm particles, 100 Å pore size) with a 140-min linear gradient from 3% to 45% acetonitrile and 0.1 % formic acid.

Both MS and MS/MS scans were acquired on the Orbitrap analyzer with a resolution of 60,000 for MS scans and 15,000 for MS/MS scans. HCD fragmentation with 35% normalized collision energy was applied. A Top Speed data-dependent MS/MS method with a fixed cycle time of 3 s was used. Dynamic exclusion was applied with a repeat count of 1 and an exclusion duration of 60 s; singly charged precursors were excluded from selection. Minimum signal threshold for precursor selection was set to 5 x  $10^4$ . Predictive AGC was

used with AGC target values of 2 x  $10^5$  for MS scans and 5 x  $10^4$  for MS/MS scans. EASY-IC was used for internal calibration.

208

#### 209 Raw data processing and database search

210 For raw-data processing, database searches and SILAC quantification, the MaxQuant 211 software version 1.5.6.5 was used (24). The search was performed against the human 212 UniProt reference proteome database (download date: 2016-12-09) plus a small database 213 containing known immunoglobulin chains. Additionally, a database containing common 214 contaminants (included in MaxQuant) was used. The search was performed with tryptic 215 cleavage specificity and 3 allowed miscleavages. Results were filtered to a false-discovery rate (FDR) <1% on protein, peptide and phosphosite level and for modified peptides a 216 217 minimum score of 40 and a minimum delta score of 6 were required. In addition to default 218 settings, protein N-terminal acetylation, Gln to pyro-Glu formation (N-term. Q), oxidation (M) 219 and phosphorylation (STY) were included as variable modifications; carbamidomethyl (C) 220 was set as fixed modification. For SILAC guantification, light (Arg0/Lys0) and heavy 221 (Arg10/Lys8) labeling were selected, with max. 4 labeled amino acids per peptide allowed; 222 matching between runs was disabled.

223 For further data analysis in R, the MaxQuant "Phospho (STY) Sites" table was processed, 224 and only phosphosites with a localization probability >0.75 and a PEP < 0.05 have been 225 included. For each experiment, the distribution of log2-transformed heavy/light SILAC ratios 226 were normalized to the first mode of the distribution. Data from replicate experiments were 227 combined, and Student's t-test as well as limma p-values were calculated and corrected for 228 multiple-hypothesis testing (Benjamini-Hochberg algorithm, FDR). In addition, boxplot 229 outliers with values outside of the 1.5x and/or the 3x interquartile range (IQR) of the 1st or 230 3rd quartile (Q1 or Q3) were labeled as significant or highly significant, only if a replicate notch, defined as 1.58\*IQR/sqrt(number of experiments), was not overlapping with the 231 232 median of all such notches.

233

#### 234 Motif logo

For calculation of position weight matrices from the phosphoproteomics data, the web tool plogo (<u>http://plogo.uconn.edu/</u>) (25) was used. Values were calculated relative to the background amino acid frequencies in the human proteome. Motif logos were then generated using the Weblogo software version 3.5.0 (26).

239

#### 240 Structures

241 Protein structures were generated using PyMol version 1.7.4.5. PDB entries 3TNP (9) and 242 3TNQ (9) were used as templates for the structures of the PKA C $\alpha$  -RII $\beta$  holoenzyme and 243 the C $\alpha$  subunit in complex with a phosphorylated substrate, respectively.

244

#### 245 Statistical analyses

Statistical analyses were performed using the Prism 6 software (GraphPad). Values are given as mean  $\pm$  s.e.m. Differences between two groups were assessed by two-tailed Student's t-test. Differences among three or more groups were assessed by two-way analysis of variance (ANOVA), followed by Bonferroni's post hoc test. Differences were considered significant for P values < 0.05.

#### 251 Results

#### 252 **PRKACA** mutations have variable effects on R subunit binding

Through genetic screening of a large series of CPAs from patients with Cushing's syndrome, 253 254 we have identified a total of 7 PRKACA mutations, including the most frequent L206R, with 255 an overall prevalence in CPAs of about 40% (10-12). The results of all available studies to 256 date are summarized in Table 1. With the exception of E32V, all mutations identified so far 257 lie at a hot spot at the interface with the R subunit (Fig. 1). Since our previous data indicated 258 that the two initially identified mutations (L206R and 199\_200insW) interfere with the 259 formation of a stable complex with the inhibitory RII<sup>β</sup> subunit (13), we first evaluated the interaction of all mutations identified so far with both RI $\alpha$  and RII $\beta$  – the two main R subunit 260 isoforms expressed in adrenocortical cells - by co-immunoprecipitation (Fig. 2 and 261 Supplementary Data, Fig. S1 (23)). 262

263 As expected, we observed a robust co-immunoprecipitation of exogenously expressed wild-264 type C $\alpha$  with both RI $\alpha$  and RII $\beta$  (Fig. 2 and Supplementary Data, Fig. S1 (23)). In the case 265 of four mutants (199\_200insW, L206R, 200\_201\_insV and S213R+insIILR), we detected 266 only faint signals in the presence of either RI $\alpha$  or RII $\beta$ , indicating that the interaction with 267 both R subunit isoforms was largely lost, consistent with our previous observations (13). 268 Unexpectedly, however, two mutants (W197R and E32V) displayed normal binding to both  $RI\alpha$  and  $RII\beta$  (Fig. 2, arrows). Of note, a previous report indicates that the W197R mutant 269 270 cannot bind to R subunits unless they are stripped off of cAMP, a condition that is not occurring in intact cells (27). The d244-248+E249Q mutant had an interesting behavior as it 271 272 showed normal binding to RII $\beta$  but a complete lack of binding to RI $\alpha$  (Fig 2, arrow). With the 273 exception of S213R+insIILR, all C $\alpha$  mutants dissociated virtually completely from R subunits 274 upon addition of cAMP (Fig. 2 and Supplementary Data, Fig. S1 (23)).

275

#### 276 **PRKACA** mutations have variable effects on PKA activity

277 Next, we investigated the activity of the C $\alpha$  mutants against the widely used synthetic 278 peptide substrate kemptide. In lysates obtained from HEK293A cells co-transfected with 279 wild-type or mutant C $\alpha$  subunits and either RI $\alpha$  or RII $\beta$ , we observed a high variability among 280 the investigated Cα mutants. A first group of mutants (199\_200insW, L206R, W197R, d244-281 248+E249Q and S213R+insIILR) was characterized by increased basal activity against kemptide at least in one condition (i.e. with RI $\alpha$  or RII $\beta$ ) (Fig. 3). The E32V mutant was 282 apparently behaving like wild-type C $\alpha$  (Fig. 3). The 200 201 insV mutant was characterized 283 284 by a strongly reduced maximal activity (measured in the presence of cAMP) against 285 kemptide compared to wild-type  $C\alpha$  (Fig. 3).

286 Unexpectedly, a different picture was observed when PKA activity was evaluated against 287 endogenous substrates in lysates of HEK293A cells transfected with the different C $\alpha$ 288 mutants and analyzed by Western blot analysis with an anti-phospho-PKA substrate 289 antibody (Supplementary Data, Fig. S2 (23)). In this assay, RII $\beta$  but not RI $\alpha$  co-expression was capable of buffering the activity of exogenous wild-type or mutant  $C\alpha$  subunits, 290 consistent with previous observations (9). Therefore, we focused on the results obtained in 291 292 the presence of RII $\beta$ . In cells co-transfected with RII $\beta$ , two C $\alpha$  mutants (199\_200insW and 293 L206R) showed strongly increased basal activity compared to wild-type  $C\alpha$  (Supplementary 294 Data, Fig. S2 (23)). The remaining mutants were characterized by a variable degree of 295 increased basal activity compared to wild-type  $C\alpha$  (Supplementary Data, Fig. S2 (23)). 296 Notably, in this assay, the 200\_201insV mutant, which was characterized by a strongly 297 reduced maximal activity in the kemptide assay, could be stimulated by addition of the adenylyl cyclase activator forskolin to a similar although slightly lower extent compared to 298 299 wild-type C $\alpha$  (Supplementary Data, Fig. S2 (23)). At a closer look, this analysis also 300 revealed potentially different phosphorylation patterns for the C $\alpha$  mutants compared to wild-301 type C $\alpha$  as well as among the C $\alpha$  mutants (Supplementary Data, Fig. S2A, arrows (23)). 302 Altogether, these data suggested the possibility that the investigated *PRKACA* mutations 303 might alter the relative preference of PKA for its substrates, so that investigating a single 304 synthetic substrate does not provide a satisfactory description of the activity of  $C\alpha$  mutants 305 against endogenous substrates.

306

#### 307 In silico analysis of PRKACA mutations predicts changes in substrate specificity

308 Our results suggested the possibility that *PRKACA* mutations might alter the preference of 309 PKA for its substrates and, thus, cause a relative change in substrate specificity. This 310 hypothesis was consistent with the location of most *PRKACA* mutations in a region of  $C\alpha$ 311 that is critical for substrate binding and recognition (27,28) (Fig. 1B). To further explore this 312 possibility, we performed an *in silico* analysis using a protein kinase substrate prediction 313 algorithm (22). The algorithm predicted relevant changes in substrate specificity for four 314 mutants: 199\_200insW, L206R, d244-248+E249Q and 200\_201insV (Fig. 1B and 315 Supplementary Data, Fig. S3 (23)). The largest change was predicted for the d244-248+E249Q mutant. For the S213R+insIILR mutant, the algorithm predicted only minor 316 317 effects on substrate specificity, whereas no changes were predicted for the two remaining 318 mutants (E32V, W197R).

319

## 320 Phosphoproteomics reveals major changes in substrate specificity caused by 321 *PRKACA* mutations

322 Motivated by the results of the Western blot analysis and the *in silico* prediction, we used a 323 quantitative phosphoproteomics approach to comprehensively analyze and quantitatively 324 compare the substrate repertoires of wild-type and mutant PKA C $\alpha$  in mammalian cells. The 325 three PKA C $\alpha$  mutations predicted to have the largest effects on substrate specificity were 326 analyzed (Fig. 4). These included the frequent L206R mutation, the d244-248+E249Q 327 mutation, which was predicted to have the strongest effect on substrate specificity, and the 328 200 201insV mutation, which shared prediction with the adjacent 199 200insW mutation. All 329 cell lysates were obtained after 30-min stimulation with the adenylyl cyclase activator 330 forskolin to allow comparison under conditions of maximal PKA activity. The 331 phosphoproteomics analysis identified 463 sites phosphorylated by the wild-type C $\alpha$  subunit. 332 A direct quantitative comparison between wild-type and mutant  $C\alpha$  subunits demonstrated 333 that the investigated PRKACA mutations caused major changes in the pattern of PKA 334 substrate phosphorylation (Fig. 4). These changes involved 62, 116 and 75 substrates that 335 were either hyper- or hypophosphorylated by the L206R, d244-248+E249Q and 336 200\_201insV mutants, respectively, compared to wild-type (Fig. 4 and Supplementary Data, 337 Dataset S1 (23)). Our data also allowed us to compute sequence logos of the region 338 encompassing the phosphoacceptor site, where the size of the letters, each corresponding 339 to a given amino acid, indicates their relative frequency at a given position (Fig. 4). Overall, 340 the analysis showed relevant changes in the preferred amino acids surrounding the 341 RR/KXpS/T phosphorylation consensus sequence, including an increased preference for amino acids with small or hydrophobic, non-aromatic side chains (glycine, alanine, valine, 342 343 methionine) at position +1 from the phosphoacceptor site, at the expense of phenylalanine 344 and other amino acids (Fig. 4). Moreover, we observed an increased preference for leucine 345 at position +1 from the phosphoacceptor site and an increased preference for acidic 346 residues in the residues downstream of the phosphoacceptor site for the L206R mutant, 347 consistent with a recent report by Lubner et al. in E. coli (29). Additionally, the L206R mutant 348 was characterized by a loss of preference for arginine residues at positions -7 to -4 relative 349 to the phosphoacceptor site and an increased preference for glutamic acid and serine at 350 several positions. For the d244-248+E249Q mutant, we found an increased preference for 351 leucine at position -1 from the phosphoacceptor site and a reduced preference for acidic 352 residues downstream of the phosphoacceptor site. The latter trend was mirrored in the 353 hypophosphorylated peptides, where acidic residues were overrepresented downstream of 354 the phosphoacceptor site. Interestingly, both mutants (L206R and d244-248+E249Q) showed an asymmetric effect on substrate phosphorylation with a higher number of peptides 355 356 that were hyperphosphorylated (40 and 93, respectively) compared to a relatively lower

357 number of hypophosphorylated ones (22 and 23, respectively). Therefore, both mutations 358 mainly seemed to increase the phosphorylation of poor substrates of the wild-type enzyme, 359 while causing only smaller decreases in the phosphorylation of other substrates. For the 360 200 201insV mutant, we observed an increased preference for leucine and alanine at 361 position -1, accompanied by a loss of preference for acidic residues downstream of the phosphoacceptor site and an increased preference for proline at position +3. The loss of 362 363 preference for peptides containing acidic residues at downstream positions was reflected by 364 their relative overrepresentation in the corresponding hypophosphorylated peptides (left panel). In contrast to the other two mutants, the 200 201 insV mutant was characterized by a 365 rather symmetric distribution with 35 hypo- and 40 hyperphosphorylated peptides, 366 367 suggesting that comparable numbers of substrates were either hyperor 368 hypophosphorylated. In general, the phosphorylation patterns differed among the three  $C\alpha$ 369 mutants. However, four substrates were consistently found to be hyperphosphorylated by all 370 three mutants compared to wild type. These were the citron rho-interacting kinase (CIT; Ser 480), the mitochondrial import receptor subunit TOM34 (Ser 93), histone H1.2 (Ser 36) and 371 372 histone H1.4 (Ser 36) (Fig. 4). H1.2, H1.4, TOM34 and CIT were also found to be present 373 and phosphorylated at the same sites in lysates of the cortisol-producing adrenocortical cell 374 line NCI-H295R (Supplementary Data, Dataset S1 (23)).

To rule out that the observed changes were due to changes in protein levels rather than phosphorylation, we performed an additional proteomics experiment on the same cell lysates, which allowed us to directly compare the relative amounts of proteins at the proteome level between wild-type and mutant samples, including, importantly, H1.2, H1.4 and TOMM34 (Supplementary Data, Fig. S4, Dataset S2 (23)). The results indicate that the levels of most proteins, including H1.2, H1.4 and TOMM34, were unchanged between wildtype and mutant samples.

382 Whereas hyperphosphorylation of CIT and TOM34 might mediate some effects of *PRKACA* 383 mutations, we concentrated our attention on H1 because phosphorylation by PKA of histone H1.4 on Ser36 – and possibly of the highly homologous Ser36 site on H1.2 – is required for
mitosis (20).

386

#### 387 *PRKACA* mutations cause histone H1.4 hyperphosphorylation *in vitro* and in CPAs

The conserved Ser36 phosphorylation site on histone H1 isoforms has been implicated in 388 389 chromatin condensation and mitosis (20). This has been better studied for histone H1.4, 390 which has been shown to be phosphorylated by PKA on Ser36 during mitosis, an event that 391 has been demonstrated to induce histone H1.4 dissociation from chromatin and be required 392 for mitosis (20). Because of the potential relevance of histone H1 Ser36 phosphorylation for 393 the mechanism of action of PRKACA mutations, we first investigated histone H1.4 394 phosphorylation in HEK293A cells transfected with Ca subunit mutants. In HEK293A cells, 395 overexpression of the L206R mutant caused a strong increase (12-fold under basal conditions; 3-fold in the presence of forskolin) in histone H1.4 Ser36 phosphorylation 396 397 compared to overexpression of wild-type C $\alpha$  (Fig. 5 and Supplementary Data, Fig. S5 (23)). 398 Modestly increased levels of histone H1.4 Ser36 phosphorylation were also observed with 399 the d244-248+E249Q and 200\_201 insV mutants compared with wild-type C $\alpha$ , even though 400 these differences did not reach statistical significance (Fig. 5 and Supplementary Data, Fig. 401 S5 (23)).

402 Furthermore, we analyzed histone H1.4 Ser36 phosphorylation in human CPA tumor samples of patients with Cushing's syndrome with or without *PRKACA* mutations (summary 403 404 of clinical data in Supplementary Data, Table S1 (23)). Importantly, a 9-fold increase in histone H1.4 Ser36 phosphorylation was observed in CPAs carrying the L206R mutation 405 406 compared with CPAs without PRKACA mutations (1.9±0.26 vs. 0.21±0.29, p=0.009) (Fig. 6). 407 These results indicated that in patients with adrenal Cushing's syndrome, at least the by far 408 most frequent L206R mutation is associated with a strong increase of H1.4 phosphorylation 409 in the patients' tumor tissue.

#### 410 **Discussion**

411 Our results indicate that *PRKACA* mutations found in CPAs alter PKA preference for its 412 targets, inducing hyperphosphorylation of several PKA substrates, including most notably 413 histone H1.4 at Ser36, which has been suggested to play an essential role in mitosis (20). 414 Thus, our study reveals another key mechanism that, together with increased PKA basal 415 activity, might explain the development of CPAs in the presence of somatic *PRKACA* 416 mutations (Supplementary Data, Fig. S6 (23)).

Whereas our previous study on the two *PRKACA* mutations intially identified in adrenal Cushing's syndrome (L206R and 199\_200insW) showed that these mutations increase basal PKA activity by preventing the binding of R subunits, the present results obtained on a larger group of *PRKACA* mutations indicate that this is not always the case (see Supplementary Data, Fig. S7 (23) for a summary of the present results), and that a relative change in PKA substrate specificity likely contributes to the mechanism of action of *PRKACA* mutations.

424 Our phosphoproteomics analysis revealed four PKA subtrates that were 425 hyperphosphorylated by all three PKA  $C\alpha$  mutants analyzed, and, thus, are potentially 426 involved in the pathogenesis of CPAs due to PRKACA mutations. These included CIT (Ser 427 480), TOM34 (Ser 93), histone H1.2 (Ser 36) and histone H1.4 (Ser 36). Importantly, all four 428 substrates were also identified to be expressed and phosphorylated on the same sites in 429 lysates of NCI-H295R cells, which are widely used as a model of differentiated, cortisol-430 producing adrenocortical cells (Supplementary Data, Dataset S1 (23)). Of these, histone 431 H1.4 and the highly homologous histone H1.2 appeared particularly intriguing because H1 432 histones play an important role in promoting, regulating and maintaining chromatin 433 organization and, thus, are deeply involved in the regulation of gene transcription and 434 mitosis (20,30-32). H1 histones possess a conserved serine residue at position 36 (Ser36), 435 which has been mainly investigated for histone H1.4. Interestingly, histone H1.4 has been 436 shown to be strongly phosphorylated on Ser36 by PKA at the first stage of mitosis

437 (prophase), to then rapidly revert to normal, low phosphorylation levels during cytokinesis 438 (20). Phosphorylation of histone H1.4 on Ser36 has been shown to promote histone H1.4 439 dissociation from mitogenic DNA and induce changes in chromatin organization (20). 440 Moreover, it has been shown that silencing H1.4 inhibits mitosis, an effect that cannot be 441 rescued by a phosphorylation-deficient H1.4 mutant (S36A) (20). These findings indicate that 442 the PKA-dependent phosphorylation of histone H1.4 at Ser36 plays an important role in 443 promoting mitosis, presumably by inducing changes in chromatin structure that are required for the realization of the mitogenic program (20). Whereas other changes in the PKA 444 445 phosphorylation pattern caused by PRKACA mutations might also play a role in the 446 pathogenesis of CPAs, it is noteworthy that two of the four hyperphosphorylated sites shared 447 by the three tested C $\alpha$  mutants are Ser36 on histone H1.4 and the corresponding Ser36 on histone H1.2, which likely plays a similar role. Our finding that histone H1.4 is highly 448 449 hyperphosphorylated in CPAs carrying the L206R mutation – but not in those with wild-type 450 PKA – supports a role of H1.4 hyperphosphorylation in the pathogenesis of CPAs due to 451 *PRKACA* mutations. Further investigations, such as studies on chromatin organization by 452 DAPI staining and H1.4-chromatin association by immunofluorescence (20) or chromatin 453 immunoprecipitation will be required to further clarify the impact of the increased H1.4 454 (Ser36) phosphorylation on chromatin organization in *PRKACA* mutated CPA tissue.

455 In addition to hyperphosphorylation of histone H1, that of CIT and of TOM34 – which, to the best of our knowledge, have not been previously reported to be phosphorylated by PKA -456 457 might also play a role in the mechanism of action of PRKACA mutations. CIT is a 458 serine/threonine-protein kinase that has been shown to be required for cytokinesis (33). 459 Phosphorylation of Ser480 might potentially influence the activity of CIT and, thus, affect 460 cytokinesis. TOM34 is involved in mitochondrial protein import (34). Interestingly, yeast 461 TOM70 has been shown to be phosphorylated by PKA on Ser174 (35), which is homologous 462 to Ser93 in human TOM34. In yeast, TOM70 phosphorylation by PKA inhibits its receptor 463 activity, which results in reduced mitochondrial import of metabolite carriers (35).

464 Phosphorylation of TOM34 at Ser93 could have a similar effect. Future studies will be 465 required to evaluate the role of CIT and TOM34 in the pathogenesis of CPAs.

466 The finding that *PRKACA* mutations cause histone H1.4 phosphorylation might help explaining why these mutations lead to the development of CPAs, while normal cAMP/PKA 467 468 signaling such as resulting from physiological stimulation by the adrenocorticotropic hormone (ACTH) has no or at most only mild proliferative effects on adrenocortical cells 469 470 (36,37). Intriguingly, this may suggest that whereas an increase in PKA activity might be 471 sufficient to induce excess cortisol production in the presence of PRKACA mutations, a 472 change in PKA substrate preference – and the resulting hyperphosphorylation of histone 473 H1.4 and possibly other targets involved in the control of cell replication – might be required 474 to stimulate cell proliferation.

Finally, our findings indicate that, given the important changes in substrate specificity caused by *PRKACA* mutations, it might be possible to develop selective orthosteric PKA inhibitors that bind only to the mutant  $C\alpha$  subunits and, thus, selectively inhibit the mutated PKA in CPAs without affecting the function of wild-type PKA in normal cells.

479 In summary, our findings indicate that *PRKACA* mutations found in CPAs lead to a change in 480 the pattern of PKA phosphorylation, which might play an important role in their mechanism of 481 action. This not only reveals a novel key mechanism potentially involved in the pathogenesis 482 of CPAs and Cushing's syndrome, but might also allow the development of selective PKA inhibitors for therapeutic purposes that block mutated but not wild-type PKA. Moreover, 483 484 these findings provide a highly illustrative example of how mutations altering substrate 485 specificity of a protein kinase might cause a human disease, which might also have 486 implications for other conditions.

487

#### 488 Author Contribution

489 D.C. designed research with contributions from M.F. and A.S. K.B., I.W. and J.W. performed

- 490 research. K.B., I.W. and J.W. analyzed data. M.F., C.L.R. and S.S. provided tumor samples
- 491 together with clinical and genetic data. K.B. and D.C. wrote the paper with contributions from
- 492 M.F., A.S., I.W., C.L.R. and S.S.

493

#### 494 Acknowledgments

495 We thank Bianca Klüpfel for excellent technical support and Ulrike Zabel for help with 496 cloning.

#### 497 **References**

- Calebiro D, Di Dalmazi G, Bathon K, Ronchi CL, Beuschlein F. cAMP signaling in
   cortisol-producing adrenal adenoma. Eur J Endocrinol 2015; 173:M99-106
- Arnaldi G, Mancini T, Tirabassi G, Trementino L, Boscaro M. Advances in the
   epidemiology, pathogenesis, and management of Cushing's syndrome
   complications. J Endocrinol Invest 2012; 35:434-448
- Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A, Tabarin A,
   Terzolo M, Tsagarakis S, Dekkers OM. Management of adrenal incidentalomas:
   European Society of Endocrinology Clinical Practice Guideline in collaboration with
   the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 2016;
   175:G1-G34
- Pierce KL, Premont RT, Lefkowitz RJ. Seven-transmembrane receptors. Nat Rev Mol
   Cell Biol 2002; 3:639-650
- 510 5. Taylor SS, Ilouz R, Zhang P, Kornev AP. Assembly of allosteric macromolecular 511 switches: lessons from PKA. Nat Rev Mol Cell Biol 2012; 13:646-658
- Søberg K, Jahnsen T, Rognes T, Skålhegg BS, Laerdahl JK. Evolutionary Paths of
   the cAMP-Dependent Protein Kinase (PKA) Catalytic Subunits. PLoS ONE 2013;
   8:e60935
- 515 7. Diskar M, Zenn H-M, Kaupisch A, Kaufholz M, Brockmeyer S, Sohmen D, Berrera M,
  516 Zaccolo M, Boshart M, Herberg FW, Prinz A. Regulation of cAMP-dependent Protein
  517 Kinases: The human protein kinase X (PrKX) reveals the role of the catalytic subunit
  518 αH-αl loop. J Biol Chem 2010; 285:35910-35918
- 519 8. Taylor SS, Buechler JA, Yonemoto W. cAMP-dependent protein kinase: framework 520 for a diverse family of regulatory enzymes. Annu Rev Biochem 1990; 59:971-1005
- 521 9. Zhang P, Smith-Nguyen EV, Keshwani MM, Deal MS, Kornev AP, Taylor SS.
  522 Structure and Allostery of the PKA RIIβ Tetrameric Holoenzyme. Science 2012;
  523 335:712-716

Beuschlein F, Fassnacht M, Assie G, Calebiro D, Stratakis CA, Osswald A, Ronchi
 CL, Wieland T, Sbiera S, Faucz FR, Schaak K, Schmittfull A, Schwarzmayr T,
 Barreau O, Vezzosi D, Rizk-Rabin M, Zabel U, Szarek E, Salpea P, Forlino A, Vetro
 A, Zuffardi O, Kisker C, Diener S, Meitinger T, Lohse MJ, Reincke M, Bertherat J,
 Strom TM, Allolio B. Constitutive activation of PKA catalytic subunit in adrenal
 Cushing's syndrome. N Engl J Med 2014; 370:1019-1028

- Di Dalmazi G, Kisker C, Calebiro D, Mannelli M, Canu L, Arnaldi G, Quinkler M,
  Rayes N, Tabarin A, Laure Jullie M, Mantero F, Rubin B, Waldmann J, Bartsch DK,
  Pasquali R, Lohse M, Allolio B, Fassnacht M, Beuschlein F, Reincke M. Novel
  somatic mutations in the catalytic subunit of the protein kinase A as a cause of
  adrenal Cushing's syndrome: a European multicentric study. J Clin Endocrinol Metab
  2014; 99:E2093-2100
- Ronchi CL, Dalmazi GD, Faillot S, Sbiera S, Assié G, Weigand I, Calebiro D,
  Schwarzmayr T, Appenzeller S, Rubin B, Waldmann J, Scaroni C, Bartsch DK,
  Mantero F, Mannelli M, Kastelan D, Chiodini I, Bertherat J, Reincke M, Strom TM,
  Fassnacht M, Beuschlein F. Genetic Landscape of Sporadic Unilateral Adrenocortical
  Adenomas Without *PRKACA* p.Leu206Arg Mutation. J Clin Endocrinol Metab 2016;
  101:3526-3538
- 542 13. Calebiro D, Hannawacker A, Lyga S, Bathon K, Zabel U, Ronchi C, Beuschlein F,
  543 Reincke M, Lorenz K, Allolio B, Kisker C, Fassnacht M, Lohse MJ. PKA catalytic
  544 subunit mutations in adrenocortical Cushing's adenoma impair association with the
  545 regulatory subunit. Nat Commun 2014; 5:5680
- 546 14. Cao Y, He M, Gao Z, Peng Y, Li Y, Li L, Zhou W, Li X, Zhong X, Lei Y, Su T, Wang
  547 H, Jiang Y, Yang L, Wei W, Yang X, Jiang X, Liu L, He J, Ye J, Wei Q, Li Y, Wang W,
  548 Wang J, Ning G. Activating hotspot L205R mutation in *PRKACA* and adrenal
  549 Cushing's syndrome. Science 2014; 344:913-917

Goh G, Scholl UI, Healy JM, Choi M, Prasad ML, Nelson-Williams C, Kunstman JW,
 Korah R, Suttorp A-C, Dietrich D, Haase M, Willenberg HS, Stalberg P, Hellman P,
 Akerstrom G, Bjorklund P, Carling T, Lifton RP. Recurrent activating mutation in
 *PRKACA* in cortisol-producing adrenal tumors. Nat Genet 2014; 46:613-617

- Sato Y, Maekawa S, Ishii R, Sanada M, Morikawa T, Shiraishi Y, Yoshida K, Nagata
  Y, Sato-Otsubo A, Yoshizato T, Suzuki H, Shiozawa Y, Kataoka K, Kon A, Aoki K,
  Chiba K, Tanaka H, Kume H, Miyano S, Fukayama M, Nureki O, Homma Y, Ogawa
  S. Recurrent somatic mutations underlie corticotropin-independent Cushing's
  syndrome. Science 2014; 344:917-920
- Nakajima Y, Okamura T, Gohko T, Satoh T, Hashimoto K, Shibusawa N, Ozawa A,
  Ishii S, Tomaru T, Horiguchi K, Okada S, Takata D, Rokutanda N, Horiguchi J,
  Tsushima Y, Oyama T, Takeyoshi I, Yamada M. Somatic mutations of the catalytic
  subunit of cyclic AMP-dependent protein kinase (*PRKACA*) gene in Japanese
  patients with several adrenal adenomas secreting cortisol [Rapid Communication].
  Endocr J 2014; 61:825-832
- 565 18. Thiel A, Reis A-C, Haase M, Goh G, Schott M, Willenberg HS, Scholl UI. *PRKACA*566 mutations in cortisol-producing adenomas and adrenal hyperplasia: a single-center
  567 study of 60 cases. Eur J Endocrinol 2015; 172:677-685
- 568 19. Espiard S, Knape MJ, Bathon K, Assié G, Rizk-Rabin M, Faillot S, Luscap-Rondof W,
  569 Abid D, Guignat L, Calebiro D, Herberg FW, Stratakis CA, Bertherat J. Activating
  570 *PRKACB* somatic mutation in cortisol-producing adenomas. JCI Insight 2018; 3
- 57120.Chu C-S, Hsu P-H, Lo P-W, Scheer E, Tora L, Tsai H-J, Tsai M-D, Juan L-J. Protein572Kinase A-mediated Serine 35 Phosphorylation Dissociates Histone H1.4 from Mitotic
- 573 Chromosome. J Biol Chem 2011; 286:35843-35851
- 574 21. Shechter D, Dormann HL, Allis CD, Hake SB. Extraction, purification and analysis of
  575 histones. Nat Protocols 2007; 2:1445-1457

- 576 22. Safaei J, Maňuch J, Gupta A, Stacho L, Pelech S. Prediction of 492 human protein
  577 kinase substrate specificities. Proteome Sci 2011; 9:1-13
- 578 23. Bathon K, Weigand I, Vanselow J, Ronchi C, Sbiera S, Schlosser A, Fassnacht M,
  579 Calebiro D. Supplementary material for: Alterations in Protein Kinase A Substrate
  580 Specificity as a Potential Cause of Cushing's Syndrome. Figshare Digital Repository
  581 Deposited 29 August 2018. https://figshare.com/s/20c9287aefcd6b69f28d;
- 582 24. Cox J, Mann M. MaxQuant enables high peptide identification rates, individualized
  583 p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotech
  584 2008; 26:1367-1372
- 585 25. O'Shea JP, Chou MF, Quader SA, Ryan JK, Church GM, Schwartz D. pLogo: a 586 probabilistic approach to visualizing sequence motifs. Nat Methods 2013; 10:1211
- 587 26. Crooks GE, Hon G, Chandonia J-M, Brenner SE. WebLogo: A Sequence Logo
  588 Generator. Genome Res 2004; 14:1188-1190
- 589 27. Gibson RM, Taylor SS. Dissecting the Cooperative Reassociation of the Regulatory 590 and Catalytic Subunits of cAMP-dependent Protein Kinase: role of Trp-196 in the 591 catalytic subunit. J Biol Chem 1997; 272:31998-32005
- 592 28. Smith CM, Radzio-Andzelm E, Madhusudan, Akamine P, Taylor SS. The catalytic 593 subunit of cAMP-dependent protein kinase: prototype for an extended network of 594 communication. Prog Biophys Mol Biol 1999; 71:313-341
- Lubner JM, Dodge-Kafka KL, Carlson CR, Church GM, Chou MF, Schwartz D.
  Cushing's syndrome mutant PKA<sup>L205R</sup> exhibits altered substrate specificity. FEBS Lett
  2017; 591:459-467
- 598 30. Fan YH, Nikitina T, Zhao J, Fleury TJ. Histone H1 depletion in mammals alters global
  599 chromatin structure but causes specific changes in gene regulation. Cell 2005;
  600 123:1199-1212

- Kim K, Choi J, Heo K, Kim H, Levens D, Kohno K, Johnson EM, Brock HW, An W.
  Isolation and Characterization of a Novel H1.2 Complex That Acts as a Repressor of
  p53-mediated Transcription. J Biol Chem 2008; 283:9113-9126
- 32. Izzo A, Schneider R. The role of linker histone H1 modifications in the regulation of
  gene expression and chromatin dynamics. Biochim Biophys Acta, Gene Regul Mech
  2016; 1859:486-495
- Gruneberg U, Neef R, Li X, Chan EHY, Chalamalasetty RB, Nigg EA, Barr FA. KIF14
  and citron kinase act together to promote efficient cytokinesis. J Cell Biol 2006;
  172:363-372
- 610 34. Faou P, Hoogenraad NJ. Tom34: A cytosolic cochaperone of the Hsp90/Hsp70
  611 protein complex involved in mitochondrial protein import. Biochim Biophys Acta, Mol
  612 Cell Res 2012; 1823:348-357
- Schmidt O, Harbauer AB, Rao S, Eyrich B, Zahedi RP, Stojanovski D, Schonfisch B,
  Guiard B, Sickmann A, Pfanner N, Meisinger C. Regulation of mitochondrial protein
  import by cytosolic kinases. Cell 2011; 144:227-239
- 616 36. Calebiro D, Bathon K, Weigand I. Mechanisms of Aberrant PKA Activation by Cα
  617 Subunit Mutations. Horm Metab Res 2017; 49:307-314
- 618 37. Fassnacht M, Hahner S, Hansen IA, Kreutzberger T, Zink M, Adermann K, Jakob F,
  619 Troppmair J, Allolio B. N-Terminal Proopiomelanocortin Acts as a Mitogen in
  620 Adrenocortical Tumor Cells and Decreases Adrenal Steroidogenesis. J Clin
  621 Endocrinol Metab 2003; 88:2171-2179

622

#### Figure legends

Fig. 1. Somatic *PRKACA* mutations identified in adrenal Cushing's Syndrome. (A) Location of the identified *PRKACA* mutations in the crystal structure of the PKA holoenzyme. Note the clustering of the *PRKACA* mutations at the interface with the R subunit. The structure of the RII $\beta_2$ :C $\alpha_2$  holoenzyme (Protein data bank/PDB entry 3TNP) was used as template. (B) Enlarged view of the PKA C $\alpha$ -RII $\beta$  interface. Shown are the positions of residues affected by *PRKACA* mutations relative to the inhibitory sequence of RII $\beta$  in the PKA RII $\beta_2$ :C $\alpha_2$  holoenzyme. The inhibitory sequence of RII $\beta$  interacts with active site cleft of C $\alpha$  and acts as a PKA substrate. Note the phosphorylated serine (S) residue within the canonical consensus for PKA phosphorylation (RRXS) in the inhibitory sequence. Most residues affected by *PRKACA* mutations participate directly or indirectly in substrate recognition. \*, Residues affected by *PRKACA* mutations participate directly or indirectly effects on substrate specificity based on *in silico* analysis. PDB entry 3TNQ was used as template.

Fig. 2. Effect of *PRKACA* mutations on the association of C<sub> $\alpha$ </sub> with R subunits. HEK293A cells were co-transfected with FLAG-tagged RII $\beta$  or RI $\alpha$  and either wild-type (WT) or mutant C $\alpha$  subunits. The association between C $\alpha$  and R subunits in the absence or presence of cAMP (200  $\mu$ M) was analyzed by co-immunoprecipitation. Samples were immunoprecipitated (IP) with an anti-FLAG antibody, followed by Western blot analysis with an antibody against C $\alpha$ . Western blot images were quantified by densitometric analysis. Data are mean±s.e.m. of three independent experiments. Arrows, mutants with conserved binding to R subunits. Differences are statistically significant by two-way ANOVA. \*P<0.05, \*\*P<0.01 and \*\*\*\*P<0.0001 vs. WT basal by Bonferroni's post hoc test. Representative Western blot images are shown in Supplementary Data, Fig. 1 (23). Fig. 3. Effect of *PRKACA* mutations on PKA activity against a synthetic substrate. HEK293A cells were co-transfected with RI $\alpha$  or RII $\beta$  and either wild-type (WT) or mutant C $\alpha$  subunits. PKA activity in cell lysates was then measured against an artificial peptide substrate (kemptide) in the presence or absence of cAMP (40  $\mu$ M). The PKA activity measured in cells transfected with the empty expression vector (pcDNA) was subtracted. Data are mean±s.e.m. of three independent experiments. Data are statistically significant by two-way ANOVA. \*P<0.05, \*\*\*P<0.001 vs. WT basal and <sup>##</sup>P<0.01, <sup>###</sup>P<0.001 vs. WT stimulated with cAMP by Bonferroni's post hoc test.

4. PRKACA mutations affect substrate specificity as revealed Fig. by **phosphoproteomics analysis.** HEK293A cells were co-transfected with RIIβ and either wild-type (WT) or mutant C $\alpha$  subunits and labeled with light amino acids (WT) or heavy amino acids (mutant). Protein lysates from these cells were then proteolytically fragmented and the resulting phosphopeptides were immunoprecipitated using a phospho-PKA substrate antibody recognizing the RR/KXpS/T consensus. Phosphopeptides were separated and detected by nanoscale liquid chromatography coupled to tandem mass spectrometry (nano LC-MS/MS). Depicted are scatter plots showing the abundance of the detected phosphopeptides in the mutant relative to wild-type samples of three independent experiments. The sequence logos report, for each mutant, the relative amino acid preferences around the consensus motif (RR/KXpS/T) for both hypo- (left) and hyperphosphorylated (right) sequences, calculated from the phosphopeptides. Values are expressed as log<sub>10</sub>-odds of the significance of overrepresentation versus the significance of underrepresentation, which are calculated using the binomial probability of residue frequencies.

Fig. 5. Effect of *PRKACA* mutations on histone H1.4 phosphorylation in HEK293A cells. HEK293A cells were co-transfected with wild-type (WT) or mutant PKA  $C\alpha$  and the

RIIβ subunit. Histone H1.4 phosphorylation was probed by Western blot analysis with an antibody specifically recognizing H1.4 phosphorylated at Ser36. A Western blot analysis for total histone H.1.4 was used as loading control. Western blot images were quantified by densitometric analysis. The adenylyl cyclase activator forskolin (10 μM) was used to induce maximal PKA activity. Data are mean±s.e.m of three independent experiments. Differences are statistically significant by two-way ANOVA. \*\*\* P<0.001 vs. WT basal and # P<0.05 vs. WT forskolin by Bonferroni's post hoc test.

**Fig. 6. Effect of** *PRKACA* **mutations on histone H1.4 phosphorylation in tumor (CPA) samples from patients with adrenal Cushing's syndrome.** Histones were extracted from CPAs with or without *PRKACA* mutations and analyzed by Western blot analysis with an antibody specifically recognizing H1.4 phosphorylated at Ser36. A Western blot analysis for total histone H1.4 was used as loading control. Western blot images were quantified by densitometric analysis. Quantified data are mean±s.e.m of 3 and 4 CPAs carrying the L206R mutation or with *PRKACA* wild-type (WT), respectively. Differences are statistically significant by unpaired t-test (\*\* P=0.009).

**Table 1.** List of somatic *PRKACA* mutations identified so far in CPAs of patients with overt

 Cushing's syndrome. Bold, studies by our group.

#### Tables

Mutation	Frequency (n mutated/total)	Reference
	36% (21/59)	(10)
	60% (33/55)	(16)
	67% (84/126)	(14)
L206R	35% (13/37)	(15)
	23% (3/13)	(17)
	34% (22/64)	(11)
	31% (11/35)	(18)
199_200insW	2% (1/59)	(10)
200_201insV	5% (3/64)	(11)
S213R+insIILR	2% (1/64)	(11)
W197R	3% (1/39)	(12)
d244-248+E249Q	3% (1/39)	(12)
E32V	3% (1/39)	(12)

Figures











Fig. 3







Fig. 5



Fig. 6